Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
Relative Value
The Relative Value of one RARE stock under the Base Case scenario is 71.94 USD. Compared to the current market price of 40.14 USD, Ultragenyx Pharmaceutical Inc is Undervalued by 44%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
RARE Competitors Multiples
Ultragenyx Pharmaceutical Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
|
3.3B USD | 7.5 | -5.4 | -5.3 | -5 | ||
US |
Abbvie Inc
NYSE:ABBV
|
284.7B USD | 5.2 | 47.8 | 13.4 | 20.7 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
164.1B USD | 5.6 | 43.6 | 18.4 | 30.4 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.6B USD | 11.5 | 29.3 | 24.6 | 25.7 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
108B USD | 8.2 | 28 | 22.6 | 25.1 | ||
AU |
CSL Ltd
ASX:CSL
|
135.3B AUD | 6.3 | 36.4 | 22 | 27.3 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
80.1B USD | 2.9 | 165.5 | 8.4 | 11.1 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
54.6B USD | 10.6 | -9.1 | -10.2 | -9.1 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
32.8B USD | 3.4 | 28.1 | 14.3 | 17.9 | ||
IE |
Horizon Therapeutics PLC
NASDAQ:HZNP
|
26.6B USD | 7.3 | 60.8 | 27.9 | 47 |